EosGene Therapeutics – Light-Controlled Nanoparticles for Safe and Precise Gene Therapy
Learn More
Safe and effective gene therapy solutions for patients with visionthreatening conditions, including retinal and rare genetic diseases
Spinout
Prototype developed
Challenge
• patients with blinding conditions like AMD require monthly eye injections that are painful, expensive, and poorly tolerated.
• gene therapies using viral vectors are risky, slow to produce, and cost millions per dose.
• the market needs scalable, affordable, and precise delivery solutions – especially for retinal and rare genetic diseases.
Solution
EosGene’ s NanoSyringe is a patented, light-triggered gene delivery platform. It enables a single IV infusion, activated only in target tissues to avoid repeat eye injections. The NanoSyringe is safer, scalable, and capable of carrying large genetic payloads, including CRISPR. Revenue will come from licensing, co-development deals, and eventual out-licensing of flagship assets, like EOS-103 for diabetic retinopathy and AMD.
Target customers / end-users
• biopharma companies seeking safer, more efficient gene delivery, especially in ophthalmology, and rare diseases
• cell / gene therapy manufacturers
Progress
• patents granted in US, EU, UK, CA, AU
• > AUD500K non-dilutive funding
• SMART CRC partner( AUD238 million program)
• validated in vivo with 13.4 × HDR efficiency
TRL 4
Multidisciplinary team
Healthy Living
With its patented non-viral platform, SMART CRC backing, strong preclinical data, and world-class team in CRISPR, nanotechnology, and clinical translation, EosGene is derisked and partner ready.
82 •